Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Alkermes 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Alkermes 1Q

Revenues up 24% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alkermes
 
1Q Revenues: $161.2 million (+24%)

1Q Loss: $30.7 million (loss of $24.4 million in 1Q14)

Comments: Manufacturing and royalty revenues from the company’s long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION were $46.9 million, down 5%. Manufacturing and royalty revenues from AMPYRA/FAMPYRA were $36.5 million, up 77%. Sales of VIVITROL were $31.1 million, up 82%. R&D expenses were up 35% to $70.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters